Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
Completed · Phase 4
Conditions studied: Chronic Diarrhea of Unknown Origin
In brief
The purpose of this study is to evaluate the effectiveness of the drug Crofelemer in the treatment of non-HIV patients with chronic idiopathic diarrhea; to determine the prevalence of identifiable causes of chronic diarrhea in a non-HIV patients; to assess the diagnostic yield, in terms of identification of treatable etiologies, of commercially available diagnostic evaluations in adult, non-HIV patients with chronic idiopathic diarrhea, that is, evaluate which tests, among the standard diagnostic tests commonly conducted as part of the evaluation of chronic idiopathic diarrhea, are most likely to identify a treatable cause of the diarrhea; and to analyze the relationship between chronic idiopathic diarrhea and health-related quality of life and assess the impact of crofelemer treatment on health-related quality of life.
Key facts
- Study ID
- NCT03898856
- Run by
- The University of Texas Health Science Center, Houston
- People needed
- 93
- Starts
- 2019-04-01
- Expected to finish
- 2025-01-30
- Last updated by the study team
- 2026-02-12
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with chronic diarrhea (defined as 3 non-bloody loose stools per day or more than 20 non-bloody loose stools per week for more ≥ 4 weeks) and Bristol Stool Form Scale for stool consistency of 6/7 with >50% stool without an obvious cause after evaluation for organic etiologies.
- Patients from any ethnicity
You may not qualify if…
- Hematochezia (potentially related to an organic cause).
- Subjects less than 18 years of age more than 75 years of age (safety and effectiveness of crofelemer has not been established in these age groups).
- Pregnant females (crofelemer is a Category C drug due to lack of well-controlled studies to study its effects in this population).
- Lactating females (it is unknown if crofelemer is excreted in the human milk and thus may have unknown adverse effects on the nursing infants).
- HIV positive individuals.
- Persons within ability to provide consent and understand the study
- Persons with history of alcohol abuse or binge drinking.
- Persons with history of surgical bowel resection or bariatric surgery in the past 12 months.
- Persons who have undergone cholecystectomy (open or laparoscopic) in the past 3 months.
- Persons receiving antibiotics currently or have received antimicrobials in the past 4 weeks.
- Persons with end-organ failures including end-stage renal disease, end-stage liver disease, or severe heart failure.
- Persons with metastatic hematologic and oncologic malignancies.
- Persons receiving chemo-radiation or immune-modulators for oncologic or rheumatologic conditions.
- Persons with any other known organic gastrointestinal or non-gastrointestinal disease process in which diarrhea is a recognized clinical feature.
- Gluten free diet for previous 3 months and refusal to ingest gluten.
Where it is running
- The University of Texas Health Science Center at Houston — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.